Wide Ranks

AMLX

Amylyx Pharmaceuticals, Inc.

5.74

Top Statistics
Market Cap 393 M Forward PE -2.52 Revenue Growth -99.60 %
Current Ratio 4.55 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -132.05 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.6510 Enterprise / Revenue 0.8230 Price To Sales Trailing12 Months 2.00
Profitability
Profit Margins -132.05 % Operating Margins -18187.74 %
Balance Sheet
Total Cash 234 M Total Cash Per Share 3.42 Total Debt 2 M
Total Debt To Equity 1.31 Current Ratio 4.55 Book Value Per Share 2.86
All Measures
Short Ratio 82.00 % Message Board Id finmb_317169670 Shares Short Prior Month 1 M
Return On Equity -0.8443 City Cambridge Uuid 1de1bf10-85d9-33d6-8204-78a28cc22479
Previous Close 5.45 First Trade Date Epoch Utc 1 B Book Value 2.86
Beta -0.6990 Total Debt 2 M Volume 616724
Price To Book 2.01 Fifty Two Week Low 1.57 Total Cash Per Share 3.42
Total Revenue 196 M Shares Short Previous Month Date 1 B Target Median Price 7.50
Audit Risk 6 Max Age 86400 Recommendation Mean 2.29
Sand P52 Week Change 0.3133 Operating Margins -18187.74 % Target Mean Price 7.50
Net Income To Common -259466000 Short Percent Of Float 0.0245 Implied Shares Outstanding 68 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 234 M Next Fiscal Year End 1 B
Revenue Per Share 2.89 Held Percent Insiders 0.1432 Ebitda Margins -126.34 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 5.45 Target Low Price 3.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 4.55 Open 5.47
Free Cashflow -78903504 State MA Dividend Yield 0.00 %
Return On Assets -0.4344 Time Zone Short Name EST Board Risk 6
Trailing Eps -3.82 Day Low 5.32 Address1 43 Thorndike Street
Shares Outstanding 68 M Compensation Risk 9 Price Hint 2
Target High Price 12.00 Website https://amylyx.com 52 Week Change -0.5946
Average Volume 1 M Forward Eps -1.85 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 438.00 % Is_sp_500 False
Regular Market Day High 5.85 Profit Margins -132.05 % Debt To Equity 1.31
Fifty Two Week High 19.95 Day High 5.85 Shares Short 1 M
Regular Market Open 5.47 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 0.8230 Revenue Growth -99.60 % Shares Percent Shares Out 0.0223
Operating Cashflow -95088000 Currency USD Time Zone Full Name America/New_York
Market Cap 393 M Is_nasdaq_100 False Zip 02141
Quote Type EQUITY Industry Biotechnology Long Name Amylyx Pharmaceuticals, Inc.
Overall Risk 8 Regular Market Day Low 5.32 Held Percent Institutions 0.8247
Current Price 5.74 Enterprise To Ebitda -0.6510 Financial Currency USD
Current Ratio 4.55 Gross Margins -50.80 % Industry Disp Biotechnology
Number Of Analyst Opinions 6 Country United States Float Shares 42 M
Two Hundred Day Average 3.99 Governance Epoch Date 1 B Enterprise Value 161 M
Price To Sales Trailing12 Months 2.00 Forward PE -2.52 Regular Market Volume 616724
Ebitda -248247008 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases.

The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

It is also developing AMX0114 for other neurodegenerative diseases.

Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.